Gritstone bio, Inc. (GRTS) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Gritstone bio, Inc. (GRTS) Healthcare & Pipeline Overview

Gritstone bio, Inc. is a clinical-stage biotechnology firm specializing in the development of novel cancer and infectious disease immunotherapies, including personalized neoantigen-based treatments and off-the-shelf solutions, positioning them within the competitive biotechnology landscape focused on innovative immune-oncology and vaccine platforms.

What Is the Investment Thesis for GRTS?

Gritstone bio, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's personalized neoantigen approach with GRANITE and its off-the-shelf SLATE immunotherapy represent potential value drivers in the oncology space. Success in clinical trials for either program could lead to significant market appreciation. The CORAL vaccine platform offers additional upside potential in the infectious disease market, particularly if it demonstrates superior efficacy against emerging SARS-CoV-2 variants. However, the company's negative profit margin of -10405.0% and gross margin of -470.3% highlight the significant financial risks associated with clinical-stage biotechnology companies. Continued funding and successful navigation of the regulatory landscape are crucial for Gritstone's long-term viability. Investors should carefully consider the inherent risks and uncertainties associated with drug development before investing.

Based on FMP financials and quantitative analysis

GRTS Key Highlights

• Gritstone bio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases.
• The company's lead product candidate, GRANITE, is a neoantigen-based immunotherapy for the treatment of solid tumors.
• Gritstone is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors.
• The company is developing CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes.
• Gritstone has strategic collaborations with bluebird bio, Inc. and Gilead Sciences, Inc.

Who Are GRTS's Competitors?

GRTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GRTS's Key Strengths?

• Innovative neoantigen-based immunotherapy platform.
• Diverse pipeline of cancer and infectious disease therapies.
• Strategic collaborations with established pharmaceutical companies.
• Experienced management team with expertise in drug development.

What Are GRTS's Weaknesses?

• Clinical-stage company with no currently approved products.
• High research and development costs.
• Dependence on successful clinical trial outcomes.
• Negative profit and gross margins.

What Could Drive GRTS Stock Higher?

• Clinical trial data releases for GRANITE in various solid tumors.
• Clinical trial data releases for SLATE in common solid tumors.
• Progress updates on the development of the CORAL vaccine platform.
• Strategic collaborations and partnerships to advance pipeline development.
• Regulatory milestones and approvals for Gritstone's product candidates.

What Are the Key Risks for GRTS?

• Financial-distress signal — its Altman Z-Score of -9.73 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Unsuccessful clinical trial outcomes for GRANITE and SLATE.
• Competition from larger pharmaceutical companies with more resources.
• Regulatory delays or rejection of Gritstone's product candidates.
• High research and development costs.
• Dependence on securing funding to support operations.

What Are the Growth Opportunities for GRTS?

• Expansion of GRANITE into additional cancer types: Gritstone's personalized neoantigen immunotherapy, GRANITE, is currently being evaluated in clinical trials for various solid tumors. Expanding the clinical development program to include additional cancer types, such as ovarian cancer or melanoma, could significantly increase the potential market for GRANITE. The market for cancer therapies is projected to reach $286 billion by 2028, offering substantial growth opportunities for successful immunotherapies.
• Advancement of SLATE through clinical trials: SLATE, Gritstone's off-the-shelf immunotherapy candidate, targets shared neoantigens common across multiple solid tumors. Successful clinical trials demonstrating the efficacy and safety of SLATE could lead to its approval and commercialization, providing a readily available treatment option for a broader patient population. The timeline for SLATE's development will depend on the progress of ongoing and future clinical trials.
• Development and commercialization of CORAL vaccine platform: Gritstone's CORAL vaccine platform is designed to deliver spike and additional SARS-CoV-2 T cell epitopes for enhanced protection against current and future variants. Successful development and commercialization of a CORAL-based vaccine could generate significant revenue, particularly if it demonstrates superior efficacy against emerging variants. The global vaccine market is projected to reach $100 billion by 2025.
• Strategic partnerships and collaborations: Gritstone has already established strategic collaborations with companies like bluebird bio, Inc. and Gilead Sciences, Inc. Expanding these partnerships or forming new collaborations with other pharmaceutical or biotechnology companies could provide access to additional resources, expertise, and funding to accelerate the development and commercialization of its product candidates. These partnerships can also help mitigate the financial risks associated with drug development.
• Expansion into new therapeutic areas: While Gritstone's primary focus is on cancer and infectious diseases, the company could explore opportunities to expand into other therapeutic areas, such as autoimmune diseases or inflammatory disorders. This diversification could broaden the company's pipeline and reduce its reliance on the success of its current product candidates. The market for autoimmune disease therapies is projected to reach $150 billion by 2027.

What Opportunities Does GRTS Have?

• Expansion of GRANITE into additional cancer types.
• Advancement of SLATE through clinical trials.
• Development and commercialization of CORAL vaccine platform.
• Expansion into new therapeutic areas.

What Threats Does GRTS Face?

• Competition from larger pharmaceutical companies.
• Regulatory hurdles and delays.
• Unsuccessful clinical trial outcomes.
• Difficulty in securing funding.

What Are GRTS's Competitive Advantages?

• Proprietary EDGE platform for identifying and targeting tumor-specific neoantigens.
• Personalized neoantigen-based immunotherapy approach.
• Off-the-shelf immunotherapy candidate targeting shared neoantigens.
• Strategic collaborations with established pharmaceutical companies.

What Does GRTS Do?

Gritstone bio, Inc., founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for the treatment of various cancers and infectious diseases. The company's primary focus is on harnessing the power of the immune system to target and eliminate cancer cells and combat infectious pathogens. Gritstone's lead product candidate, GRANITE, is a personalized neoantigen-based immunotherapy designed for solid tumors, including metastatic non-small cell lung cancer, gastroesophageal cancer, bladder cancer, and microsatellite stable colorectal cancer. This personalized approach involves identifying unique mutations (neoantigens) within a patient's tumor and creating a customized immunotherapy to target those specific mutations. In addition to GRANITE, Gritstone is developing SLATE, an 'off-the-shelf' immunotherapy candidate targeting shared neoantigens common across various solid tumors, such as metastatic non-small cell lung cancer, colorectal cancer, and pancreatic cancer. This off-the-shelf approach aims to provide a more readily available treatment option for a broader patient population. Furthermore, Gritstone is actively engaged in developing vaccines, including CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for enhanced protection against current and future variants. They are also working on a therapeutic vaccine candidate aimed at treating and potentially curing HIV infection. Gritstone has established strategic collaborations with companies like bluebird bio, Inc. and Gilead Sciences, Inc., and maintains a license agreement with Genevant Sciences GmbH, to further advance its research and development efforts.

What Products and Services Does GRTS Offer?

• Develop personalized neoantigen-based immunotherapies for cancer treatment.
• Create off-the-shelf immunotherapies targeting shared neoantigens in common solid tumors.
• Design and develop vaccines for infectious diseases, including SARS-CoV-2 and HIV.
• Conduct clinical trials to evaluate the safety and efficacy of their immunotherapy and vaccine candidates.
• Establish strategic collaborations with other pharmaceutical and biotechnology companies.
• Utilize their proprietary EDGE platform to predict and target tumor-specific neoantigens.

How Does GRTS Make Money?

• Develop and out-license immunotherapies and vaccines to pharmaceutical companies.
• Generate revenue through research and development collaborations with other companies.
• Potentially manufacture and sell their own products if clinical trials are successful and regulatory approval is obtained.
• Focus on discovering and developing novel immunotherapies and vaccines.

What Industry Does GRTS Operate In?

Gritstone bio, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for cancer immunotherapies is experiencing significant growth, driven by the increasing prevalence of cancer and the limitations of traditional treatment options. The development of effective vaccines against infectious diseases, such as SARS-CoV-2 and HIV, also represents a significant market opportunity. Gritstone's personalized neoantigen approach and off-the-shelf immunotherapy platform position it to potentially capture a share of this growing market, but it faces competition from larger, more established pharmaceutical companies and other emerging biotechnology firms.

Who Are GRTS's Key Customers?

• Pharmaceutical companies seeking to license or acquire novel immunotherapies and vaccines.
• Patients with cancer and infectious diseases who may benefit from Gritstone's therapies.
• Healthcare providers who prescribe and administer Gritstone's therapies.
• Government agencies and non-profit organizations involved in public health initiatives.

GRTS Valuation & Market Position

With a $3.80M market cap, Gritstone bio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GRTS's quantitative score of 44/100 is below the peer average of 82/100.

FY2026 estForward Outlook

Wall Street analysts project Gritstone bio, Inc. revenue of about $35.0M for fiscal 2026, with EPS near $-0.32.

F-Score 1/9Financial Health

Gritstone bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.73 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -77.9%, showing how much profit it generates from its asset base. A current ratio of 3.20 indicates the company holds enough short-term assets to cover its near-term obligations.

GRTS Financials

GRTS Latest News

GRTS Analyst Consensus

GRTS MoonshotScore

Common Questions About GRTS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources